Spots Global Cancer Trial Database for Phase I Study of Sequential Cord Blood Transplants
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of Sequential Cord Blood Transplants
Official Title: Phase I Study of Sequential Cord Blood Transplants
Study ID: NCT00299767
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have a matched family or volunteer unrelated donor.
Detailed Description: Eligible patients will receive conditioning therapy with fludarabine 30 mg/m2/day x 6 days, melphalan 100 mg/m2/day x 1 day, rabbit antithymocyte globulin 1.5 mg/kg/day x 4 days. GVHD prophylaxis will consist of cyclosporine starting on day -1 and mycophenolate mofetil starting on day 0. Sequential cord blood units will be infused on Day 0.
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Contact Details
Name: Karen Ballen, M.D.
Affiliation: Massachusetts General Hospital, Harvard University
Role: PRINCIPAL_INVESTIGATOR
Name: Joseph Antin, M.D.
Affiliation: Dana Farber Cancer Institute, Harvard Univeristy
Role: PRINCIPAL_INVESTIGATOR
Name: David Avigan, M.D.
Affiliation: Beth Israel Deaconess Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
